Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Did Hedge Funds Drop The Ball On Nevro Corp (NVRO) ?

World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients’ money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. It’s not surprising then that they generate their biggest returns from these stocks and invest more of their money in these stocks on average than other investors. It’s also not surprising then that we pay close attention to these picks ourselves and have built a market-beating investment strategy around them.

Is Nevro Corp (NYSE:NVRO) a healthy stock for your portfolio? Prominent investors are reducing their bets on the stock. The number of long hedge fund positions were cut by 4 in recent months. Our calculations also showed that nvro isn’t among the 30 most popular stocks among hedge funds.

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey’s flagship best performing hedge funds strategy returned 20.7% year to date (through March 12th) and outperformed the market even though it draws its stock picks among small-cap stocks. This strategy also outperformed the market by 32 percentage points since its inception (see the details here). That’s why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.

SAC CAPITAL ADVISORS

We’re going to take a glance at the recent hedge fund action encompassing Nevro Corp (NYSE:NVRO).

How are hedge funds trading Nevro Corp (NYSE:NVRO)?

At Q4’s end, a total of 20 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -17% from one quarter earlier. The graph below displays the number of hedge funds with bullish position in NVRO over the last 14 quarters. With hedge funds’ sentiment swirling, there exists an “upper tier” of notable hedge fund managers who were adding to their stakes considerably (or already accumulated large positions).

No of Hedge Funds with NVRO Positions

Among these funds, Point72 Asset Management held the most valuable stake in Nevro Corp (NYSE:NVRO), which was worth $51.3 million at the end of the fourth quarter. On the second spot was D E Shaw which amassed $51.2 million worth of shares. Moreover, Millennium Management, Citadel Investment Group, and Broadfin Capital were also bullish on Nevro Corp (NYSE:NVRO), allocating a large percentage of their portfolios to this stock.

Since Nevro Corp (NYSE:NVRO) has witnessed a decline in interest from the entirety of the hedge funds we track, it’s easy to see that there is a sect of hedgies who were dropping their positions entirely in the third quarter. It’s worth mentioning that Mitchell Blutt’s Consonance Capital Management said goodbye to the largest position of the 700 funds tracked by Insider Monkey, totaling about $82.4 million in stock. Samuel Isaly’s fund, OrbiMed Advisors, also cut its stock, about $77.4 million worth. These bearish behaviors are important to note, as total hedge fund interest dropped by 4 funds in the third quarter.

Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as Nevro Corp (NYSE:NVRO) but similarly valued. We will take a look at Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Frank’s International N.V. (NYSE:FI), PROS Holdings, Inc. (NYSE:PRO), and TiVo Corporation (NASDAQ:TIVO). All of these stocks’ market caps are similar to NVRO’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
SGMO 23 79711 -3
FI 12 24473 1
PRO 15 111619 -1
TIVO 19 90952 1
Average 17.25 76689 -0.5

View table here if you experience formatting issues.

As you can see these stocks had an average of 17.25 hedge funds with bullish positions and the average amount invested in these stocks was $77 million. That figure was $296 million in NVRO’s case. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is the most popular stock in this table. On the other hand Frank’s International N.V. (NYSE:FI) is the least popular one with only 12 bullish hedge fund positions. Nevro Corp (NYSE:NVRO) is not the most popular stock in this group but hedge fund interest is still above average. Our calculations showed that top 15 most popular stocks) among hedge funds returned 24.2% through April 22nd and outperformed the S&P 500 ETF (SPY) by more than 7 percentage points. Hedge funds were also right about betting on NVRO as the stock returned 65.7% and outperformed the market by an even larger margin. Hedge funds were rewarded for their relative bullishness.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...